EIDD-1931, also known as NHC, is primarily studied for its antiviral properties, particularly in the treatment of RNA virus infections. It has shown promise in inhibiting the replication of viruses such as influenza, Ebola, and coronaviruses, including SARS-CoV-2. The compound works by introducing errors into the viral RNA during replication, effectively reducing the virus's ability to spread and cause disease. Its potential application extends to both therapeutic and prophylactic uses, making it a candidate for treating active infections and preventing viral outbreaks. Research is ongoing to evaluate its efficacy, safety, and potential use in combination with other antiviral therapies.